Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revumenib plus intensive chemotherapy for newly diagnosed NPM1-mutated acute myeloid leukemia
jRCT2051260190Phase 3Not yet recruiting
- Sponsor
- Syndax Pharmaceuticals
- Start
- Dec 2026
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Revumenib + intensive chemotherapy with Placebo + intensive chemotherapy (2 arms). Primary endpoints: Event-free survival and Measurable residual disease complete remission rate. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
revumenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on jRCT2051260190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051260190.